knowledge -WSS

knowledge

author：leisure time 2025-08-12 09:11:20 - browse：7742

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： CVS is willing to dump 10% of its Medicare Advantage members

focus

WSS

Biohaven protein

Supreme Court to hear if Covid misinformation is protected speech

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Novo Nordisk testing Wegovy against alcohol

Lab trade group sues FDA to halt regulation of lab

Oak Street deal isn't the answer to health care's woes

hotspot

knowledge

explore

Heart attack and stroke risk calculators need revising

Startling documents reveal new facets of Sacklers' opioid empire

At least 13 dead in Texas as scorching temps continue

Antibiotic resistance nearly killed me, so I'm raising awareness of it

How one medical school became remarkably diverse

CVS is willing to dump 10% of its Medicare Advantage members

Peter Hotez and the public health issue of online harassment

Lab trade group sues FDA to halt regulation of lab

23andMe had bad news about my health. I wish a person had delivered it

Oak Street deal isn't the answer to health care's woes

hotspot

Health insurers say they are turning to AI to cut costs, improve care

Average age of first period drops to 11.9 years, study shows

Insmed lung disease drug hits target in key Phase 3 trial

Scientists successfully use ultrasound imaging to map brain activity

Scientists successfully use ultrasound imaging to map brain activity

Latest bird flu infection made farmworker sicker than earlier cases

leisure time

entertainment

focus

explore